GlassScriptPhysician profile
Zubda Rashid
NPI 1699707497
$1,734.70
in general payments reported to CMS, 2019-2025
27 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $297 · 2021: $395 · 2022: $396 · 2024: $33.52 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.00 | 2019-2022 | |
| Amgen INC. | $189.03 | 2019-2022 | |
| Daiichi Sankyo INC. | $189.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.41 | 2019-2025 | |
| Mylan Pharmaceuticals INC. | $113.05 | 2021-2022 | |
| Therapeuticsmd, INC. | $83.39 | 2019-2021 | |
| Astellas Pharma US INC | $78.26 | 2022-2025 | Veozah |
| Evofem Biosciences, INC. | $75.72 | 2021-2022 | |
| Coopersurgical, INC. | $64.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $64.75 | 2019-2020 | |
| Agile Therapeutics, INC. | $64.54 | 2021-2022 | |
| Covidien LP | $55.89 | 2019-2020 | |
| Avion Pharmaceuticals | $53.22 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $46.13 | 2019-2020 | |
| Convatec INC. | $41.07 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $34.98 | 2025 | Freestyle Libre 3 |
| Duchesnay USA Incorporated | $34.22 | 2019 | |
| Medtronic, INC. | $31.72 | 2022 | |
| Exeltis, USA INC. | $25.59 | 2020-2021 | |
| Organon LLC | $24.31 | 2022 | |
| Myovant Sciences INC. | $21.26 | 2022 | |
| Alydia Health | $18.75 | 2021 | |
| Lupin INC. | $17.63 | 2019 | |
| Hologic Sales and Service, LLC | $15.92 | 2021 | |
| Shield Therapeutics INC | $14.21 | 2025 | |
| Millicent US INC | $13.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zubda Rashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.